Marijuana Rescheduling: What Moving From Schedule I to Schedule III Means
Background
On December 18, 2025, President Trump issued an Executive Order directing the Department of Justice to complete the rulemaking process to reschedule marijuana from Schedule I to Schedule III under the Controlled Substances Act. This shift reflects federal recognition of marijuana’s accepted medical use and opens the door to regulated prescription and expanded commercial activity. Marijuana rescheduling also brings meaningful changes to federal tax, banking, research, and enforcement frameworks, easing long-standing barriers that have constrained the cannabis industry. While marijuana would remain a federally regulated substance and is not fully legalized nationwide, the move to Schedule III represents a major step forward—delivering significant benefits for cannabis operators, ancillary service providers, and municipalities alike.
Table of Contents
Understanding Marijuana’s Federal Rescheduling
Reclassifying marijuana from Schedule I to Schedule III marks a major shift in how cannabis is treated under federal law, recognizing its accepted medical use and lower potential for abuse. Most notably, this change eliminates the IRS Section 280E restriction, allowing state-legal cannabis businesses to deduct ordinary business expenses and significantly improve profitability. As a result, this will support long-term compliance, local employment, and reliable tax revenues. Rescheduling also accelerates opportunities for scientific research and clinical trials by formally acknowledging marijuana’s medical benefits.
While marijuana remains federally regulated and is not fully legalized, Schedule III status reduces federal penalties and creates a more favorable operating environment. Cannabis products will continue to be sold through state-licensed dispensaries—not pharmacies—since marijuana is not an FDA-approved drug. Even with these limitations, rescheduling represents a meaningful step forward for the industry, delivering real financial, research, and regulatory advantages.
Legal and Regulatory Implications for New York
The rescheduling of marijuana to Schedule III does not replace New York’s Office of Cannabis Management regulatory framework. Local zoning authority and existing operational requirements remain in full effect, and compliance risks persist for operators, landlords, investors, and municipalities. Federal-State tension persists, particularly around financing, interstate activity, and relationships with federally regulated counterparties. Importantly, rescheduling is not federal legalization—activity outside state authorization can still carry significant legal consequences. These dynamics are especially pronounced in property use, leasing, and municipal oversight, where federal classification, state licensing, and local control converge.
When evaluating how marijuana rescheduling may impact a project, transaction, or policy decision, stakeholders should consider the following legal checklist:
Licensing and Regulatory Compliance: Confirm that all New York licenses, permits, and approvals remain valid and appropriately scoped, and assess whether Schedule III status introduces new federal or state reporting, medical-use, or compliance considerations.
Federal Agency Oversight: Assess ongoing exposure to federal agencies such as the DEA, FDA, IRS, or HUD, recognizing that Schedule III may shift—but does not eliminate—regulatory scrutiny, audit risk, or enforcement priorities.
Property Use & Zoning Conflicts: Verify zoning compliance, certificates of occupancy, and local opt-in requirements, and evaluate whether rescheduling meaningfully affects lender, insurer, or title company risk tolerance.
Leasing & Contractual Exposure: Review leases, development agreements, municipal approvals, and management contracts for cannabis-specific provisions, including use restrictions, termination rights, compliance representations, and risk allocation tied to changes in law.
Financing & Investment Risk: Examine loan covenants, equity structures, and public financing mechanisms for cannabis-related restrictions or disclosure obligations, and determine whether assumptions about reduced federal risk are supportable post-rescheduling.
Rescheduling represents an incremental policy shift—not a break from federal prohibition, and these issues are best addressed proactively. A targeted legal review during this transition can help stakeholders uncover hidden risks, strengthen deal structures, and confidently capitalize on the evolving cannabis landscape while minimizing exposure.
When to Contact Legal Counsel About Marijuana Rescheduling
As marijuana rescheduling evolves, developers, property owners, cannabis operators, and municipalities should engage counsel when projects, leases, or policy decisions involve regulated cannabis activity or assume reduced federal risk. Partial federal reform creates legal gray areas as agencies update guidance, increasing the risk of compliance gaps and shifting interpretations. A proactive legal review can help confirm licensing compliance, assess ongoing federal oversight, identify zoning or lender conflicts, and ensure contracts and financing structures properly allocate cannabis-related risk. Early guidance during this transition can prevent costly delays, renegotiations, and disputes. Contact The West Firm to get started.
-
Marijuana rescheduling may shift how federal agencies prioritize enforcement, but it does not eliminate oversight or enforcement authority by agencies such as the DEA, FDA, or IRS over noncompliant or unauthorized cannabis activity.
-
No, Schedule III status does not override New York zoning laws or municipal land-use controls, and local governments retain authority to regulate where and how cannabis uses are permitted.
-
Property owners must remain mindful of zoning, lending, insurance, lease, and federal compliance considerations, particularly when cannabis operations extend beyond state authorization or regulatory requirements.
.png?content-type=image%2Fpng)